Q32 Bio Inc. (QTTB) research

Q32 Bio Inc.
ShareXLinkedInReddit
Sector
Healthcare
Industry
Biotechnology
Last price
$10.54
As of

Q32 Bio Inc. (QTTB): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-14.

As of . Source: SEC EDGAR filings for QTTB. Method and limitations.

SHARE THIS CARD

Share the QTTB intelligence card

A branded snapshot of QTTB: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion QTTB intelligence card preview
Post to X
LIVE TERMINAL

See QTTB live in the terminal

Track QTTB's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live QTTB terminal, free

Active signals for QTTB

FREE, NO ACCOUNT

Every signal on QTTB, as it fires

You are seeing 5 of 17 signals recorded on QTTB since 2026-06-03.

The five above all landed on 2026-09-06. The other 12 were recorded on 4 other days. 12 of the 17 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in QTTB (2026Q2)

Manager / securityMarket value% portfolioQoQ
Point72 Asset Management, L.P.CUSIP 746964105 · 2026Q2$14.9M0.02%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 746964105 · 2026Q2$2.3M0.00%,
CITADEL ADVISORS LLCCUSIP 746964105 · 2026Q2$1.5M0.00%,
TWO SIGMA INVESTMENTS, LPCUSIP 746964105 · 2026Q2$632K0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP 746964105 · 2026Q2$139K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, QTTB

QTTB against its peers

QTTB's operating margin of 31.5% ranks in the 97th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-05-31.

MetricQTTBPeer medianPercentilen
Revenue FY53.7M USD31.4M USD6417
Operating margin31.5%-201.1%9714
Net margin55.5%-186.5%9115
Return on equity71.0%-42.2%9819
P / E4.4xn/an/a2

Peers (23): ABEO, SABS, SION, VNDA, AGEN, IKT, IFRX, EYPT, STRO, IPSC, FATE, CMPX, LXEO, ZNTL, UPB, EBS, IMRX, CYDY, ENTA, XFOR, OCGN, OBIO, PYXS. Left out: VCRE (no annual filing), CUVL (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (QTTB: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more QTTB signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to QTTBand get the insider, 13F, options, and confluence read in one view.

Open the live QTTB terminal, free